Literature DB >> 22285382

Paraoxonase activity in healthy, diabetic, and hemodialysis patients.

Nagba Yendoubé Gbandjaba1, Noreddine Ghalim, Mohamed Hassar, Hicham Berrougui, Halima Labrazi, Hassan Taki, Rachid Saile, Abdelouahed Khalil.   

Abstract

OBJECTIVES: Paraoxonase 1 (PON1) is mainly complexed to HDL and is responsible, at least in part, for their antioxidant properties. The aims of our study were to determine the phenotype distribution and enzymatic activities of PON1 and the oxidative stress status of healthy subjects and diabetic and hemodialysis patients. DESIGN AND METHODS: PON1 paraoxonase and arylesterase activities and oxidative stress markers [malondialdehyde (MDA) and vitamin E levels] were measured in 300 individuals as a function of health status.
RESULTS: The prevalence of the PON1 phenotypes in the study population was 74.51%, 18.15% and 7.34% for QQ, QR and RR, respectively. The phenotype distribution did not change significantly as a function of health status (healthy, diabetes, hemodialysis). However, the hemodialysis patients had lower PON1 paraoxonase and arylesterase activities than the diabetic patients and healthy subjects, while there were no significant differences between the diabetic patients and the healthy subjects. Oxidative stress markers (MDA levels and vitamin E/cholesterol ratio) were significantly higher in the diabetic and hemodialysis patients than in the healthy subjects.
CONCLUSIONS: The lower plasma PON1 enzymatic activities in the hemodialysis patients was not associated with a difference in the phenotype distribution of PON1. Oxidative stress conditions were significantly higher in these patients, which may increase the risk of atherosclerosis in this population.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285382     DOI: 10.1016/j.clinbiochem.2012.01.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  12 in total

1.  Relation of Paraoxonase 1 Activity with Biochemical Variables, Brachial Artery Intima-Media Thickness in Patients with Diabetes with or without Obesity.

Authors:  Pinar Karakaya; Bahar Ozdemir; Meral Mert; Yildiz Okuturlar
Journal:  Obes Facts       Date:  2018-02-14       Impact factor: 3.942

2.  Role of Ankaferd on bacterial translocation and inflammatory response in an experimental rat model of intestinal obstruction.

Authors:  Velat Sen; Unal Uluca; Aydın Ece; Ali Güneş; Hikmet Zeytun; Serkan Arslan; Ibrahim Kaplan; Gül Türkçü; Recep Tekin
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes.

Authors:  Mehryar Zargari; Fahimeh Sharafeddin; Abdolkarim Mahrooz; Ahad Alizadeh; Parisa Masoumi
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

Review 4.  Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.

Authors:  Chiz-Tzung Chang; Chao-Yuh Yang; Fuu-Jen Tsai; Shih-Yi Lin; Chao-Jung Chen
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

5.  Vitamin B6 supplementation improves oxidative stress and enhances serum paraoxonase/arylesterase activities in streptozotocin-induced diabetic rats.

Authors:  Sibel Taş; Emre Sarandöl; Melahat Dirican
Journal:  ScientificWorldJournal       Date:  2014-11-06

6.  Establishment of combined analytical method to extract the genes of interest from transcriptome data.

Authors:  Akinori Ishihara; Hidenori Yamanaka; Reiko Takahashi; Tomomi Numajiri; Saki Kaneko; Yoko Ishizawa; Sakuji Koya; Kiyoshi Yamauchi
Journal:  Biochem Biophys Rep       Date:  2016-05-19

7.  The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy.

Authors:  Diling Wu; Chenfang Wu; Yanjun Zhong
Journal:  J Cell Mol Med       Date:  2018-07-07       Impact factor: 5.310

8.  Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients.

Authors:  Alicja E Grzegorzewska; Paulina Adamska; Ewa Iwańczyk-Skalska; Kamila Ostromecka; Leszek Niepolski; Wojciech Marcinkowski; Adrianna Mostowska; Wojciech Warchoł; Czesław Żaba; Paweł P Jagodziński
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

9.  Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population.

Authors:  Abdelghani Bounafaa; Hicham Berrougui; Noreddine Ghalim; Boubker Nasser; Abdallah Bagri; Abderrahmane Moujahid; Souad Ikhlef; Pamela Camponova; Najoua Yamoul; Olivier Kamtchueng Simo; Abdelkhalid Essamadi; Abdelouahed Khalil
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

10.  Low paraoxonase 1 activity predicts mortality in surgical patients with sepsis.

Authors:  Suzana Bojic; Jelena Kotur-Stevuljevic; Nevena Kalezic; Zorana Jelic-Ivanovic; Aleksandra Stefanovic; Ivan Palibrk; Lidija Memon; Zdravko Kalaba; Marina Stojanovic; Sanja Simic-Ogrizovic
Journal:  Dis Markers       Date:  2014-02-09       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.